CL2017001089A1 - Vacunas terapéuticas contra el vph16 - Google Patents

Vacunas terapéuticas contra el vph16

Info

Publication number
CL2017001089A1
CL2017001089A1 CL2017001089A CL2017001089A CL2017001089A1 CL 2017001089 A1 CL2017001089 A1 CL 2017001089A1 CL 2017001089 A CL2017001089 A CL 2017001089A CL 2017001089 A CL2017001089 A CL 2017001089A CL 2017001089 A1 CL2017001089 A1 CL 2017001089A1
Authority
CL
Chile
Prior art keywords
hpv
vaccines against
therapeutic vaccines
protein
polypeptides
Prior art date
Application number
CL2017001089A
Other languages
English (en)
Inventor
Evelien M Bunnik
Jerome H H V Custers
Gerrit Ch Scheper
Koen Oosterhuis
Taco Gilles Uil
Selina Khan
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52020908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017001089(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of CL2017001089A1 publication Critical patent/CL2017001089A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)

Abstract

<p>LA INVENCIÓN PROPORCIONA CONSTRUCCIONES DE ÁCIDOS NUCLÉICOS DISEÑADORES Y POLIPÉPTIDOS QUE PUEDEN UTILIZARSE COMO VACUNAS TERAPÉUTICAS CONTRA VPH16. ESTOS POLIPÉPTIDOS COMPRENDEN ESENCIALMENTE TODOS LOS EPÍTOPOS DE CÉLULAS T POSIBLES DE ONCOPROTEÍNAS E6 Y E7 DEL VPH 16, PERO, NO OBSTANTE, TIENEN UNA ACTIVIDAD TRANSFORMANTE FUERTEMENTE REDUCIDA (EN COMPARACIÓN CON E6 Y E7XT) HASTA NO DETECTABLE, QUE COMPRENDEN FRAGMENTOS DE LAS PROTEÍNAS E6 Y E7 QUE HAN SIDO RE-ORDENADAS, CONTENIENDO AL MISMO TIEMPO UN NUMERO MINIMIZADO DE NEO-EPÍTOPOS INDESEADOS. LA INVENCIÓN PROPORCIONA UNA MOLÉCULA DE ACIDO NUCLÉICO QUE CODIFICA UN POLIPÉPTIDO QUE COMPRENDE UNA SECUENCIA COMO LA RECOGIDA EN LA SEQ. ID NO: 1. EN DETERMINADAS REALIZACIONES, EL POLIPÉPTIDO CODIFICADO COMPRENDE, ADEMÁS, AL MENOS UN EPÍTOPO DE UNA PROTEÍNA E2 DEL VIRUS DEL PAPILOMA HUMANO (VPH), POR EJEMPLO UNA PROTEÍNA E2 DE VPH 16.</p>
CL2017001089A 2014-11-04 2017-05-02 Vacunas terapéuticas contra el vph16 CL2017001089A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14191660 2014-11-04

Publications (1)

Publication Number Publication Date
CL2017001089A1 true CL2017001089A1 (es) 2017-12-29

Family

ID=52020908

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001089A CL2017001089A1 (es) 2014-11-04 2017-05-02 Vacunas terapéuticas contra el vph16

Country Status (33)

Country Link
US (4) US9701721B2 (es)
EP (2) EP3421046A1 (es)
JP (2) JP6325751B2 (es)
KR (1) KR20170083562A (es)
CN (1) CN107075521B (es)
AR (1) AR102527A1 (es)
AU (2) AU2015341926B2 (es)
BR (1) BR112017009177A2 (es)
CA (1) CA2965562C (es)
CL (1) CL2017001089A1 (es)
CO (1) CO2017004838A2 (es)
CY (1) CY1121377T1 (es)
DK (1) DK3215187T3 (es)
EA (1) EA035461B1 (es)
ES (1) ES2697903T3 (es)
HR (1) HRP20181895T1 (es)
HU (1) HUE040440T2 (es)
IL (1) IL251895B (es)
LT (1) LT3215187T (es)
MA (2) MA46378A (es)
MD (1) MD3215187T2 (es)
MX (1) MX2017005788A (es)
MY (1) MY181175A (es)
NZ (1) NZ730802A (es)
PL (1) PL3215187T3 (es)
PT (1) PT3215187T (es)
RS (1) RS58080B1 (es)
SA (1) SA517381457B1 (es)
SG (1) SG11201702997YA (es)
SI (1) SI3215187T1 (es)
TW (2) TWI731654B (es)
WO (1) WO2016071306A1 (es)
ZA (1) ZA201703055B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201702997YA (en) 2014-11-04 2017-05-30 Janssen Vaccines & Prevention Bv Therapeutic hpv16 vaccines
MX2018002106A (es) 2015-08-20 2018-06-15 Janssen Vaccines & Prevention Bv Vacunas terapeuticas contra el hpv18.
CA3021341A1 (en) * 2016-05-02 2017-11-09 Janssen Vaccine & Prevention B.V. Therapeutic hpv vaccine combinations
CN112574317B (zh) * 2017-01-24 2023-12-05 南京益康生物医药有限公司 一种重组蛋白及药物组合物与应用
EP3675903A1 (en) 2017-09-23 2020-07-08 Boehringer Ingelheim Vetmedica GmbH Paramyxoviridae expression system
US20200399348A1 (en) * 2018-02-20 2020-12-24 Emory University HPV Proteins, Antibodies, and Uses in Managing Abnormal Epithelial Cell Growth
JP2021517895A (ja) * 2018-03-12 2021-07-29 スクイーズ バイオテクノロジーズ カンパニー Ｈｐｖ関連疾患を処置するための方法
EP3810277A1 (en) * 2018-07-20 2021-04-28 Janssen Vaccines & Prevention B.V. Recombinant adenoviral vector expressing zika antigen with improved productivity
CN108992665B (zh) * 2018-08-06 2021-11-19 南京颂悦生物科技有限公司 基于重组减毒单增李斯特菌的宫颈癌治疗性疫苗
CN108939064B (zh) * 2018-08-06 2021-12-10 南京颂悦生物科技有限公司 基于重组减毒绵羊李斯特菌的宫颈癌治疗性疫苗
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信
EP4031573A1 (en) 2019-09-20 2022-07-27 Transgene Combination of a poxvirus encoding hpv polypeptides and il-2 with an anti-pd-l1 antibody
US20230277645A1 (en) * 2020-04-02 2023-09-07 Inovio Pharmaceuticals, Inc. Compositions and methods for treating vulvar dysplasia
US20210315986A1 (en) 2020-04-13 2021-10-14 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
US20210353744A1 (en) * 2020-05-12 2021-11-18 Janssen Vaccines Prevention B.V. Administration of homologous adenoviral vectors
TW202228769A (zh) 2020-11-24 2022-08-01 佳揚生物科技股份有限公司 用於人類乳突病毒的ｄｎａ疫苗及其使用方法
AU2022371672A1 (en) * 2021-10-22 2024-05-16 Inovio Pharmaceuticals, Inc. Compositions and methods for treating anal high-grade squamous intraepithelial lesion (hsil)

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
EP1548118A2 (en) 1994-06-10 2005-06-29 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
ES2333425T5 (es) 1995-06-15 2012-08-28 Crucell Holland B.V. Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2177085C (en) 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
CA2283253A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
PT1816204E (pt) 1999-05-17 2011-01-24 Crucell Holland Bv Adenovírus recombinante do serótipo ad26
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
FR2794370B1 (fr) 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
EP2100620A1 (en) * 1999-09-16 2009-09-16 Eisai Corporation of North America Nucleic acids encoding polyepitope polypeptides
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
WO2002029088A2 (en) 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Highly expressible genes
EE05680B1 (et) 2000-11-23 2013-10-15 Bavarian Nordic A/S Muundatud vaktsiiniaviirus, selle valmistamine ja kasutamine, seda sisaldav farmatseutiline kompositsioon ning vaktsiin
AU2002257420A1 (en) 2001-05-01 2002-11-11 National Research Council Of Canada A system for inducible expression in eukaryotic cells
BR0308783A (pt) 2002-04-25 2005-01-04 Crucell Holland Bv Vetor de adenovìrus recombinante, método para produzir um vetor de adenovìrus recombinante, composição farmacêutica, método para tratar um corpo humano, e, kit de partes
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
AU2005222776A1 (en) * 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
NZ548495A (en) 2004-02-23 2009-05-31 Crucell Holland Bv Virus purification methods
JP5291341B2 (ja) 2004-11-08 2013-09-18 クロマジェニックス ベー ヴェー タンパク質を高レベルで発現する宿主細胞の選定
WO2007073513A2 (en) 2005-11-10 2007-06-28 Genvec, Inc. Method for propagating adenoviral vectors encoding inhibitory gene products
EA014757B1 (ru) 2006-02-28 2011-02-28 Вэксарт, Инк. Химерный аденовирусный вектор, иммуногенная композиция на его основе, способ индукции иммуного ответа с его помощью и выделенная нуклеиновая кислота
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
ATE518958T1 (de) * 2007-01-30 2011-08-15 Transgene Sa Zur impfung verwendetes papillomavirus-e2- polypeptid
DE102008010954A1 (de) * 2008-02-25 2009-08-27 Cichon, Günter, Prof.Dr. DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen
EA019928B1 (ru) 2008-11-03 2014-07-30 Круселл Холланд Б.В. Способ получения аденовирусных векторов
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
BR112012019023B1 (pt) 2010-02-15 2021-12-21 Janssen Vaccines & Prevention B.V. Método para produzir adenovírus recombinante sorotipo 26 (rad26), e, uso de um biorreator
PL2604629T3 (pl) * 2010-08-13 2018-08-31 Genexine, Inc. Kompozycja do zapobiegania lub leczenia raka szyjki macicy ze wzmacniaczem odporności przeciwko wirusowi brodawczaka ludzkiego
EP2780034A1 (en) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
EP2601968A1 (en) * 2011-12-06 2013-06-12 Deutsches Krebsforschungszentrum HPV derived polynucleic acids for therapy
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
AU2015310909B2 (en) 2014-09-03 2021-05-27 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara (MVA) filovirus vaccine
SG11201702997YA (en) 2014-11-04 2017-05-30 Janssen Vaccines & Prevention Bv Therapeutic hpv16 vaccines
MX2018002106A (es) 2015-08-20 2018-06-15 Janssen Vaccines & Prevention Bv Vacunas terapeuticas contra el hpv18.
CA3021341A1 (en) * 2016-05-02 2017-11-09 Janssen Vaccine & Prevention B.V. Therapeutic hpv vaccine combinations

Also Published As

Publication number Publication date
MA46378A (fr) 2019-08-07
ES2697903T3 (es) 2019-01-29
SG11201702997YA (en) 2017-05-30
RS58080B1 (sr) 2019-02-28
EP3215187B1 (en) 2018-08-29
JP6325751B2 (ja) 2018-05-16
CA2965562A1 (en) 2016-05-12
US10071151B2 (en) 2018-09-11
HRP20181895T1 (hr) 2019-01-11
SI3215187T1 (sl) 2019-02-28
EP3421046A1 (en) 2019-01-02
TWI694147B (zh) 2020-05-21
MX2017005788A (es) 2017-08-02
US20160122396A1 (en) 2016-05-05
PT3215187T (pt) 2018-11-27
AU2015341926A1 (en) 2017-04-27
LT3215187T (lt) 2018-12-27
US20170281747A1 (en) 2017-10-05
JP2017534286A (ja) 2017-11-24
MA40902B1 (fr) 2018-12-31
PL3215187T3 (pl) 2019-04-30
SA517381457B1 (ar) 2021-03-11
MD3215187T2 (ro) 2019-02-28
ZA201703055B (en) 2019-11-27
HUE040440T2 (hu) 2019-03-28
KR20170083562A (ko) 2017-07-18
CN107075521B (zh) 2021-06-08
DK3215187T3 (en) 2018-12-10
CO2017004838A2 (es) 2017-07-28
AU2015341926B2 (en) 2018-09-27
CY1121377T1 (el) 2020-05-29
AU2018282463A1 (en) 2019-01-24
NZ730802A (en) 2021-12-24
AR102527A1 (es) 2017-03-08
BR112017009177A2 (pt) 2018-12-11
EA035461B1 (ru) 2020-06-19
TW201617450A (zh) 2016-05-16
JP2018148890A (ja) 2018-09-27
IL251895A0 (en) 2017-06-29
US20200164057A1 (en) 2020-05-28
CA2965562C (en) 2023-11-21
US20180344841A1 (en) 2018-12-06
WO2016071306A1 (en) 2016-05-12
TW202043476A (zh) 2020-12-01
TWI731654B (zh) 2021-06-21
US10555996B2 (en) 2020-02-11
MY181175A (en) 2020-12-21
EA201790976A1 (ru) 2017-09-29
US11040096B2 (en) 2021-06-22
IL251895B (en) 2019-08-29
CN107075521A (zh) 2017-08-18
US9701721B2 (en) 2017-07-11
AU2018282463B2 (en) 2020-09-10
MA40902A (fr) 2017-09-13
JP6606571B2 (ja) 2019-11-13
EP3215187A1 (en) 2017-09-13

Similar Documents

Publication Publication Date Title
CL2017001089A1 (es) Vacunas terapéuticas contra el vph16
CO2018001623A2 (es) Vacunas terapéuticas contra el hpv18 y/o hpv16
CL2018000740A1 (es) Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden
EA201591287A1 (ru) Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения
CL2018002825A1 (es) Vacuna contra vrs
CL2018000587A1 (es) Adenovirus oncolítico que codifica una proteína b7 (divisional de sol. n° 2731-2017)
MX2017012097A (es) Variantes de virus adenoasociado y métodos de uso de estas.
DOP2016000316A (es) Dinucleótidos cíclicos como moduladores de sting
EA201890999A1 (ru) Вакцина против вируса простого герпеса
CR20180174A (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer
BR112016020688A2 (pt) Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
EA201891415A8 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
BR112015021884A2 (pt) vetores compreendendo sequências de polinucleotídeos de stuffer/agente de enchimento e métodos de uso
BR112016007868A2 (pt) vacinas contra o vírus de epstein-barr
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
MX354516B (es) Vectores que codifican el factor de viabilidad de conos derivado de bastones.
AR108781A1 (es) Aumento de la inmunogenicidad del péptido l2 de virus de papiloma humano (hpv)
UY33297A (es) Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas
NZ702146A (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
UY33525A (es) Nuevo polietilenglicol, estable conjugado de interferón alfa, representado por un isómero de posición
CL2017003341A1 (es) Vectores virales recombinantes que contienen la proteína menor del virus del síndrome reproductor y respiratorio porcino (prrsv) y sus métodos de elaboración y uso
DOP2017000287A (es) Analogos glp-1 lipidados resistentes a proteasa
NZ753370A (en) Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine
EA201592298A1 (ru) Полуживая вирусная вакцина против респираторно-синцитиального вируса